Healthcare rant of the week: When husband was sick and admitted to the hospital there was a complete division between inpatient and outpatient medicine even at the same hospital. Creates havoc and bad patient care IMHO. Let me count the ways 1/7

I'm honored to join the phenomenal thoracic group Memorial Sloan Kettering Cancer Center as we continue working with the global oncology community to advance care for our patients worldwide with groundbreaking new discoveries and practice-changing therapies. #LCSM mskcc.org/news-releases/…

Dr. Noura Choudhury, MD: impact of brain metastases on ML-6070 (DLL3 BiTE) at #WCLC24. Brain metastases permitted at entry if treated, asymptomatic, & stable for at least 2w. Pts with SRS for isolated CNS metastases did well on therapy. 25% of pts had baseline CBS lesions resolve.

Wonderful to share sessions with esteemed friend Michael Offin to talk about developing better treatments for our respective rare cancer focuses! IASLC #WCLC24

1/ Ty IASLC #WCLC24 scientific committee for selecting our in progress work on defining presenting features and diagnostic delays of NUT carcinoma meetingsapp.iaslc.org/event/wclc2024…

#WCLC24 Gʀᴇɢᴏʀʏ Rɪᴇʟʏ on updated encorafenib/ binimetinib safety data for BRAF V600E NSCLC with no significant changes in expected GI AEs/ safety - Always learning how to give great talks from watching Dr Riely 😉 - Great recent FDA approval for pts: fda.gov/drugs/resource…

Just posted on mskcc.org/news - incredibly moving story about the index patient in our recent study on chromothripsis-mediated small cell lung carcinoma. x.com/natasharekhtma… Khaliq Sanda was a 19 yo premed student when he received the diagnosis. Our entire team was

I feel that in the midst of many excellent oral presentations at #WCLC24, posters don't get enough love, even when they describe highly novel and clinically relevant findings. This my [modest] attempt to spotlight some of the posters at #WCLC24 that I really enjoyed [THREAD]

Combination targeted therapies of independent but cooperating pathways, an understudied therapeutic strategy for prolonged disease control (cures?) ascopubs.org/doi/10.1200/PO… Arielle Elkrief, MD FRCPC Igor Odintsov Gʀᴇɢᴏʀʏ Rɪᴇʟʏ Robert C. Doebele, MD, PhD #LCSM #LCSM Chat Basse Clémence EGFR Resisters RETpositive

I enjoyed this commentary by my Bob Maki and Alexia Iasonos and colleagues MSK Department of Medicine Memorial Sloan Kettering Biostatistics Service Journal of Clinical Oncology helping understand a new approach to integrating efficacy and toxicity. ascopubs.org/doi/10.1200/JC…

💊 Update on Pharos trial: Encorafenib plus binimetinib in BRAF V600E metastatic NSCLC presented by Gʀᴇɢᴏʀʏ Rɪᴇʟʏ 🌟 Impressive 30 months PFS for Tx-naive patients. ORR 75% DoR 40 months #ESMOAmbassadors #ESMO24 #LCSM

Dr. Gʀᴇɢᴏʀʏ Rɪᴇʟʏ at #ESMO24 presents update from phase II PHAROS study of encorafenib plus binimetinib in #BRAF V600E NSCLC. In treatment naive setting, RR 75% with mDOR 40m, mPFS 30.2m. In previously treated, RR 46%, mDOR 16.7m, mPFS 9.3m.

#ESMO24 In treatment naive setting, encorafenib + binimetinib for #BRAF V600E NSCLC has not reached median OS, 3y OS rate 53%. In previously treated, mOS 22.7m. In the update, no new safety concerns with relatively low rates of fevers (8% and all grade 1-2). #ESMOAmbassadors

Update Gʀᴇɢᴏʀʏ Rɪᴇʟʏ on PHAROS trial (Encorafenib + Binimetinib) for BRAFv600E mutated NSCLC ✅ Important data for treatment naive patients: ORR 75%, mPFS 30.2mo DoR 40 months mOS NE #lcsm #ESMO24

We'd like to congratulate Alan Ho on his new role as Chief of the Head and Neck Oncology Service within the Division of Solid Tumor Oncology in the Department of Medicine at MSK. Learn more about Dr. Ho ➡️ bit.ly/3ZI1qVB #ESMO24

Exciting data! Melissa L. Johnson Sarah Cannon Docs

Dr Lu presents LAURA CNS and distant PD data. Distant PD rate 16 vs 37%. 55% PET scan staging. PFS HR similar. TTDM HR=0.22. CNS PFS HR=0.17 #ESMO24 ESMO - Eur. Oncology

Sanjay Popat ESMO - Eur. Oncology Stunning to see practically 100% recurrence/progression rate even in PET staged patients - stage 3 EGFR+ NSCLC is indeed stage 4 in disguise- imo justifying the extended course of “adjuvant” EGFR TKI tx

AMG 193 in MTAP deleted rumours. Important trial. Should be part of work up for many thoracic malignancies #ESMO24

Excited and honored to co-lead our newly-established Center of Excellence for Gynecologic Cancer Mount Sinai Health System with the amazing Stephanie Blank.